“…Other studies [7,8,10,11,19], including platform trials [5,6], have reported a favorable effect of tocilizumab in alpha, beta or gamma cases; however, the benefit of tocilizumab in patients infected with delta, which is reported to be more virulent [20], or in patients infected with omicron, which is, in contrast, reputed to be less virulent [21], remained disputable. To the best of our knowledge, this study was the first to report the use of tocilizumab in a large cohort of severe COVID-19 patients infected with the delta and omicron VOC, suggesting that, among the patients developing a severe form of the disease, the mortality rates were similar in the omicron and delta cases, as it has been reported with previous VOCs [14].…”